Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172600265> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W3172600265 endingPage "2639" @default.
- W3172600265 startingPage "2639" @default.
- W3172600265 abstract "2639 Background: Pembrolizumab, a PD-1 immune checkpoint inhibitor (ICI), has demonstrated significant clinical activity in various cancers. Despite a favorable toxicity profile, discontinuation due to adverse events including immune related adverse events (irAE) has been reported. We conducted a meta-analysis of published clinical trials to evaluate the tolerability of pembrolizumab in cancer patients. Methods: A systematic review was conducted of relevant studies from the databases of PubMed and abstracts presented at American Society of Clinical Oncology (ASCO) from June 2015 until September 2020. Eligible studies included prospective clinical trials that reported a discontinuation rate due to adverse effects. Incidence, relative risk and 95% confidence intervals (CI) were calculated by employing fixed or random effects models. Results: A total of 6,380 patients with a variety of hematologic and solid malignancies from 20 studies of pembrolizumab were included for analysis. The overall rate of pembrolizumab discontinuation due to adverse events was 8.2% (95% CI: 6.4-10.4%). The discontinuation rate of pembrolizumab was not significantly lower than the chemotherapy controls, with RR of 0.84 (95% CI: 0.58-1.12, p = 0.33). However, the discontinuation rate of pembrolizumab was significantly higher compared to placebo control with RR of 2.20 (95% CI: 1.36-3.54, p < 0.001), and significantly lower compared to ipilimumab with RR of 0.58 (95% CI: 0.34-0.99, p = 0.04) respectively. The discontinuation rate varied widely among different tumor types with the lowest rate of 0.8% (95% CI: 0.2-3%) in gastric cancer, and the highest of 13.5% (95% CI: 10.8-16.8%) in head and neck squamous cell carcinoma. Interestingly, the discontinuation rate varied with pembrolizumab dosing, with the fixed dosing of 200mg being 9.2% (95% CI: 6.9-12%) and the weight-based dosing being 6.5% (95% CI: 4.8-8.8%). The weight-based dosing was associated with a significantly lower discontinuation rate compared to controls with RR of 0.62 (95% CI: 0.47-0.81, p < 0.0001), while the fixed dosing had similar discontinuation rate with RR of 1.03 (95% CI: 0.89-1.20, p = 0.67). Conclusions: The tolerability of pembrolizumab may be comparable to chemotherapy in cancer patients and may vary with its dosing. Future studies are warranted to evaluate the impact of different dosing." @default.
- W3172600265 created "2021-06-22" @default.
- W3172600265 creator A5020103730 @default.
- W3172600265 creator A5071756910 @default.
- W3172600265 creator A5075193275 @default.
- W3172600265 date "2021-05-20" @default.
- W3172600265 modified "2023-09-23" @default.
- W3172600265 title "Improving tolerability of pembrolizumab with weight based dosing: A meta-analysis." @default.
- W3172600265 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.2639" @default.
- W3172600265 hasPublicationYear "2021" @default.
- W3172600265 type Work @default.
- W3172600265 sameAs 3172600265 @default.
- W3172600265 citedByCount "1" @default.
- W3172600265 countsByYear W31726002652022 @default.
- W3172600265 crossrefType "journal-article" @default.
- W3172600265 hasAuthorship W3172600265A5020103730 @default.
- W3172600265 hasAuthorship W3172600265A5071756910 @default.
- W3172600265 hasAuthorship W3172600265A5075193275 @default.
- W3172600265 hasConcept C121608353 @default.
- W3172600265 hasConcept C126322002 @default.
- W3172600265 hasConcept C142724271 @default.
- W3172600265 hasConcept C143998085 @default.
- W3172600265 hasConcept C197934379 @default.
- W3172600265 hasConcept C204787440 @default.
- W3172600265 hasConcept C27081682 @default.
- W3172600265 hasConcept C2777701055 @default.
- W3172600265 hasConcept C2778375690 @default.
- W3172600265 hasConcept C2778715236 @default.
- W3172600265 hasConcept C2780057760 @default.
- W3172600265 hasConcept C2781433595 @default.
- W3172600265 hasConcept C71924100 @default.
- W3172600265 hasConceptScore W3172600265C121608353 @default.
- W3172600265 hasConceptScore W3172600265C126322002 @default.
- W3172600265 hasConceptScore W3172600265C142724271 @default.
- W3172600265 hasConceptScore W3172600265C143998085 @default.
- W3172600265 hasConceptScore W3172600265C197934379 @default.
- W3172600265 hasConceptScore W3172600265C204787440 @default.
- W3172600265 hasConceptScore W3172600265C27081682 @default.
- W3172600265 hasConceptScore W3172600265C2777701055 @default.
- W3172600265 hasConceptScore W3172600265C2778375690 @default.
- W3172600265 hasConceptScore W3172600265C2778715236 @default.
- W3172600265 hasConceptScore W3172600265C2780057760 @default.
- W3172600265 hasConceptScore W3172600265C2781433595 @default.
- W3172600265 hasConceptScore W3172600265C71924100 @default.
- W3172600265 hasIssue "15_suppl" @default.
- W3172600265 hasLocation W31726002651 @default.
- W3172600265 hasOpenAccess W3172600265 @default.
- W3172600265 hasPrimaryLocation W31726002651 @default.
- W3172600265 hasRelatedWork W137885780 @default.
- W3172600265 hasRelatedWork W2344038060 @default.
- W3172600265 hasRelatedWork W2475687906 @default.
- W3172600265 hasRelatedWork W2963968387 @default.
- W3172600265 hasRelatedWork W3016822790 @default.
- W3172600265 hasRelatedWork W3023502736 @default.
- W3172600265 hasRelatedWork W3082399821 @default.
- W3172600265 hasRelatedWork W3107203411 @default.
- W3172600265 hasRelatedWork W3172600265 @default.
- W3172600265 hasRelatedWork W4223500234 @default.
- W3172600265 hasVolume "39" @default.
- W3172600265 isParatext "false" @default.
- W3172600265 isRetracted "false" @default.
- W3172600265 magId "3172600265" @default.
- W3172600265 workType "article" @default.